Adverse Effects of ATG/ALG Therapy in Aplastic Anemia

Institute of Hematology & Blood Diseases Hospital, China

Status: Enrolling

Conditions: Aplastic Anaemia

Treatments: Drug: ATG/ALG

Study type: Observational

Funder types: Other

Identifiers

NCT07461116

AA-ATG/ALG-20260108

Details and patient eligibility

About

This prospective, single-center, observational cohort study aims to systematically observe and describe the clinical characteristics of adverse reactions in patients with aplastic anemia undergoing ATG (Anti-Thymocyte Globulin) /ALG (Anti-Lymphocyte Globulin) treatment, providing a data foundation for the development of relevant management strategies. This study plans to enroll 200 aplastic anemia patients undergoing ATG/ALG treatment

Enrollment: 200 estimated patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Meet the diagnostic criteria for aplastic anemia (Camitta criteria);
• Receiving ATG/ALG immunosuppressive therapy for the first time;

Exclusion criteria

• Previously received hematopoietic stem cell transplantation;
• Aplastic anemia patients receiving ATG/ALG as part of transplant conditioning regimen;

Trial design

200 participants in 1 patient group

Patients with aplastic anemia undergoing ATG or ALG treatment

Treatment:

Drug: ATG/ALG